The Conversation (0)
ETF Trends reported that healthcare exchange-traded funds continue to perform well despite “the biotechnology meltdown that started late in the first quarter and lasted into the early second quarter.”
ETF Trends reported that healthcare exchange-traded funds continue to perform well despite “the biotechnology meltdown that started late in the first quarter and lasted into the early second quarter.”
As quoted in the market news:
Thought the end of the the third quarter, the Health Care Select Sector SPDR (NYSEArca: XLV) was easily the top performer among the nine sector SPDR ETFs, rising 16.5%, according to ETF Replay data. XLV’s performance was 280 basis points better than the second-best SPDR, the Utilities Select Sector SPDR (NYSEArca: XLU), and beat the S&P 500 by a two-to-one margin.
‘The health-care sector in general and XLV in particular have progressed from a sweet spot to a sweeter spot to an even sweeter spot between June 2012 and September 2014,’ writes J.J. McGrath in a Seeking Alpha post.